Drs. Brian O’Neill and Val Rakita Explain the Role of the Impella Pump in the National Cardiogenic Shock Initiative Study

Ivanhoe Broadcast News produced a segment about Temple University Hospital’s participation in the National Cardiogenic Shock Initiative study, which showed 72 percent of patients with cardiogenic shock survived their heart attack when treated with a specific protocol. The protocol involves quickly recognizing the condition and then inserting the Impella pump, an FDA-approved device, through a catheter in the groin as soon as the patient arrives at the hospital. Doctors then treat the cause of the heart attack. Brian O’Neill, MD, Associate Professor of Medicine at the Lewis Katz School of Medicine at Temple University (LKSOM) and Val Rakita, MD, Assistant Professor of Medicine at LKSOM, were interviewed for the piece, which was picked up by media outlets including KXAS-TV in Dallas-Fort Worth, Texas; KSAT-TV in San Antonio, Texas; KFSN-TV in Fresno, California; WMC-TV in Memphis, Tennessee; and WFMZ-TV in Allentown, Pennsylvania.